



**Corp. Off.:-** 201, "The Summit Business Bay"  
Behind Guru Nanak Petrol Pump,  
Off Andheri Kurla Road, Andheri (E),  
Mumbai - 400 093 (India)  
Ph. : +91 22 69073100

14<sup>th</sup> February, 2023

**BSE Limited**

Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai-400001  
Scrip Code: 533543

**National Stock Exchange of India Ltd.**

Exchange Plaza, C-1, Block G  
Bandra Kurla Complex  
Bandra (E), Mumbai-400051  
Symbol: BROOKS

**Sub: Outcome of Board Meeting**

**Ref: Disclosure under Regulation 30 & Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015**

Dear Sir/Madam,

This is with reference to the regulation mentioned above:

In continuation of our intimation dated February 3, 2023 and pursuant to Regulation 30 & Regulation 33 and other applicable regulations of the LODR, we wish to inform you that the Board of Directors of the Company, at its meeting held today, i.e. February 14, 2023, has inter alia approved the Unaudited Financial Results (Standalone and Consolidated) for the quarter and nine months ended December 31, 2022.

We attach herewith a copy of the approved Unaudited Standalone and Consolidated Financial Results for the quarter and nine months ended December 31, 2022 alongwith the Limited Review Report of the Auditors.

The meeting started at 2:30 PM and concluded at 4:30 PM

This is for your information and record.

Thanking You,

Yours faithfully

For **BROOKS LABORATORIES LIMITED**

JAI

VAIDYA

(Jai Vaidya)

Company Secretary cum Compliance Officer

Membership No. A42246

Encl.: As Stated Above

Digitally signed by JAI VAIDYA  
Date: 2023.02.14 16:37:22  
+05'30'



Statements of Unaudited Financial Results for the Quarter and Nine Months ended 31st December, 2022.

Particulars	Standalone						Consolidated					
	Quarter Ended		31-Dec-21	Nine Months ended		Year Ended	Quarter Ended		31-Dec-21	Nine Months ended		Year Ended
	31-Dec-22	30-Sep-22		31-Dec-22	31-Dec-21		31-Mar-22	31-Dec-22		30-Sep-22	31-Dec-22	
	Unaudited			Unaudited		Audited	Unaudited			Unaudited		Audited
<b>1 Income</b>												
Revenue from operations	1,200.27	1,589.49	1,812.03	4,284.04	5,430.23	7,696.72	1,530.32	1,808.09	1,900.83	5,050.77	6,261.54	9,107.72
Other income	6.03	6.51	22.15	17.16	193.83	94.76	9.21	13.70	36.80	26.32	72.60	90.91
<b>Total income</b>	<b>1,206.30</b>	<b>1,596.00</b>	<b>1,834.18</b>	<b>4,301.20</b>	<b>5,624.06</b>	<b>7,791.48</b>	<b>1,539.53</b>	<b>1,821.79</b>	<b>1,937.63</b>	<b>5,077.09</b>	<b>6,334.14</b>	<b>9,198.63</b>
<b>2 Expenses</b>												
(a) Cost of materials consumed	728.94	835.73	1,399.19	2,399.29	3,141.55	4,648.83	983.70	887.61	1,545.33	3,320.97	4,042.31	6,293.45
(b) Purchase of Stock in Trade	83.23	191.01	32.74	553.33	434.96	571.65	63.09	86.48	11.03	428.66	130.26	195.85
(c) Change in inventories of finished goods, work-in-progress and stock-in-trade	48.65	87.19	(68.55)	272.53	5.29	(292.56)	103.35	499.58	(79.93)	490.08	231.75	(210.47)
(d) Employees benefits expenses	292.98	279.93	329.20	927.90	940.81	1,280.19	414.42	522.36	499.37	1,507.93	1,369.69	1,914.95
(e) Finance Costs	24.02	18.51	13.13	58.24	43.65	66.97	74.76	62.84	74.15	199.89	225.44	309.69
(f) Depreciation and amortization expenses	42.09	42.95	36.07	128.19	106.82	148.63	232.93	227.99	188.31	659.13	540.03	735.07
(g) Other expenses	193.81	222.57	279.09	708.84	889.48	1,301.17	821.13	734.59	563.15	1,940.94	1,532.50	2,349.86
<b>Total Expenses</b>	<b>1,414.52</b>	<b>1,677.89</b>	<b>2,020.87</b>	<b>5,048.32</b>	<b>5,562.56</b>	<b>7,724.88</b>	<b>2,693.38</b>	<b>3,021.45</b>	<b>2,801.41</b>	<b>8,547.60</b>	<b>8,071.98</b>	<b>11,588.40</b>
<b>3 Profit/(Loss) before Share of Profit / (Loss) of Associate, exceptional item and tax</b>	<b>(208.22)</b>	<b>(81.89)</b>	<b>(186.69)</b>	<b>(747.12)</b>	<b>61.50</b>	<b>66.60</b>	<b>(1,153.85)</b>	<b>(1,199.66)</b>	<b>(863.78)</b>	<b>(3,470.51)</b>	<b>(1,737.84)</b>	<b>(2,389.77)</b>
<b>4 Share of Profit / (Loss) of Associate Profit/(Loss) before Exceptional item and tax</b>	<b>(208.22)</b>	<b>(81.89)</b>	<b>(186.69)</b>	<b>(747.12)</b>	<b>61.50</b>	<b>66.60</b>	<b>(1,153.50)</b>	<b>(1,173.15)</b>	<b>(863.78)</b>	<b>(3,443.65)</b>	<b>(1,737.84)</b>	<b>(2,389.77)</b>
<b>5 Exceptional items (Refer Note No 4)</b>	-	-	-	-	-	-	35.67	-	-	35.67	-	-
<b>6 Profit/(Loss) from ordinary activities before tax</b>	<b>(208.22)</b>	<b>(81.89)</b>	<b>(186.69)</b>	<b>(747.12)</b>	<b>61.50</b>	<b>66.60</b>	<b>(1,117.83)</b>	<b>(1,173.15)</b>	<b>(863.78)</b>	<b>(3,407.98)</b>	<b>(1,737.84)</b>	<b>(2,389.77)</b>
<b>7 Tax Expense:</b>												
Deferred Tax Liability / (Assets)	-	-	-	-	-	-	(169.67)	(385.48)	(123.38)	(732.40)	(400.11)	(468.51)
MAT credit reversal	-	-	-	-	-	-	-	-	-	-	-	-
Tax of earlier years	-	-	-	-	-	-	-	-	-	-	-	-
<b>8 Net Profit/(loss) after tax</b>	<b>(208.22)</b>	<b>(81.89)</b>	<b>(186.69)</b>	<b>(747.12)</b>	<b>61.50</b>	<b>66.60</b>	<b>(948.16)</b>	<b>(787.67)</b>	<b>(740.40)</b>	<b>(2,675.58)</b>	<b>(1,337.73)</b>	<b>(1,931.26)</b>
<b>9 Other Comprehensive Income</b>												
<b>Items That will not be reclassified into Profit or loss</b>												
Actuarial Gain/ (Loss) on Defined Benefit Plans (Net of Tax)	-	-	(2.95)	-	(8.87)	8.85	-	-	(2.96)	-	(8.87)	2.73
Gain on remeasuring FVTPL financial assets	-	-	-	-	-	3.81	-	-	-	-	-	3.81
<b>10 Total Comprehensive income for the period</b>	<b>(208.22)</b>	<b>(81.89)</b>	<b>(186.63)</b>	<b>(747.12)</b>	<b>52.63</b>	<b>79.26</b>	<b>(948.16)</b>	<b>(787.67)</b>	<b>(743.36)</b>	<b>(2,675.58)</b>	<b>(1,346.60)</b>	<b>(1,924.72)</b>
<b>Net Profit attributable to</b>												
Owners of equity	-	-	-	-	-	-	(501.90)	(468.19)	(661.13)	(1,660.15)	(1,258.45)	(1,618.75)
Non Controlling Interest	-	-	-	-	-	-	(446.26)	(319.48)	(79.27)	(1,015.43)	(79.28)	(312.51)
<b>Other Comprehensive Income attributable to</b>												
Owners of equity	-	-	-	-	-	-	-	-	(2.96)	-	(8.87)	9.01
Non Controlling Interest	-	-	-	-	-	-	-	-	-	-	-	(2.47)
<b>Total Comprehensive Income attributable to</b>												
Owners of Equity	-	-	-	-	-	-	(501.90)	(468.19)	(664.09)	(1,660.15)	(1,267.33)	(1,609.74)
Non Controlling Interest	-	-	-	-	-	-	(446.26)	(319.48)	(79.27)	(1,015.43)	(79.27)	(314.98)
<b>11 Paid-up equity share capital (Face Value of Rs. 10 each)</b>	<b>2,470.28</b>	<b>2,470.28</b>	<b>2,470.28</b>	<b>2,470.28</b>	<b>2,470.28</b>	<b>2,470.28</b>	<b>2,470.28</b>	<b>2,470.28</b>	<b>2,470.28</b>	<b>2,470.28</b>	<b>2,470.28</b>	<b>2,470.28</b>
<b>12 Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of previous year.</b>	<b>4,030.02</b>	<b>4,030.02</b>	<b>3,950.76</b>	<b>4,030.02</b>	<b>3,950.76</b>	<b>3,950.76</b>	<b>6,278.72</b>	<b>6,278.72</b>	<b>5,444.56</b>	<b>6,278.72</b>	<b>5,444.56</b>	<b>5,444.56</b>
<b>13 Earnings per share (of Rs. 10/- each) (not annualised)</b>												
(a) Basic	(0.84)	(0.33)	(0.77)	(3.02)	0.21	0.27	(2.03)	(3.19)	(2.68)	(6.72)	(5.09)	(7.82)
(b) Diluted	(0.84)	(0.33)	(0.77)	(3.02)	0.21	0.27	(2.03)	(3.19)	(2.68)	(6.72)	(5.09)	(7.82)

Notes:

- The above Financial Results of the Company have been reviewed by the Audit committee and approved by the Board of Directors at their respective meeting held on 14 February, 2023
- The financial results have been prepared in accordance with Indian Accounting Standard ("Ind AS") prescribed under section 133 of the Companies Act 2013, read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015 (as amended) and SEBI Circular Dated 5th July, 2016
- The Consolidated Financial Results have been prepared in accordance with Ind AS 110 on "Consolidated Financial Statements" and Ind AS 28 on "Investments in Associates and Joint Ventures".
- During the quarter ended December 31, 2022, the Company has lost control over its subsidiary company Brooks Steriscience Limited,(BSL) and the Company now jointly controls the entity along with its JV partner and has accounted accordingly subsequent to loss of control. The Company has accordingly, derecognised the assets and liabilities of the former subsidiary from the consolidated balance sheet and has recognised retained investment at fair value when control is lost. Gain on loss of control over BSL amounting to Rs 35.67 lacs has been credited to the profit and loss account under exceptional item.
- The Company operates in one reportable business segment i.e "Pharmaceuticals".
- Figures of the previous reporting period has been reclassified/ regrouped wherever necessary to correspond with the figures of the current reporting period.

For and on Behalf of the Board

*Omish*  
 Kausalya Singh  
 Din No: 09244596  
 Whole Time Director



# **SGCO & Co. LLP**

**Chartered Accountants**

Limited Review Report on Unaudited Standalone Financial Results of Brooks Laboratories Limited for the Quarter and Nine Months ended on December 31st, 2022, pursuant to the Regulation 33 of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015

To,  
The Board of Directors of  
Brooks Laboratories Limited

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of Brooks Laboratories Limited (The "Company"), for the Quarter and Nine Months ended on December 31st, 2022. This Statement which is the responsibility of the Company's Management and approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement.
3. A review is limited primarily to inquiries of company personnel and analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in all material respects in accordance with Ind AS and other recognized accounting practices and policies, and has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For S G C O & Co. LLP**  
Chartered Accountants  
Firm's Registration No. 112081W/W100184



**Suresh Murarka**

Partner

Mem. No. 044739

UDIN : 23044739BGUNLM2155

Place : Mumbai

Date : 14<sup>th</sup> February 2023

4A, Kaledonia,  
2nd Floor, Sahar Road,  
Near Andheri Station,  
Andheri (East),  
Mumbai - 400 069

Tel. +91 22 6625 6363  
Fax. +91 22 6625 6364  
E-mail. info@sgco.co.in  
www.sgco.co.in



# **SGCO & Co. LLP**

**Chartered Accountants**

Limited Review Report on Unaudited Consolidated Financial Results for the Quarter and Nine Months ended December 31st, 2022 of Brooks Laboratories Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To,  
The Board of Directors of  
**Brooks Laboratories Limited**

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of **Brooks Laboratories Limited** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the Quarter and Nine Months ended December 31st, 2022 ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entities:
- Brooks Laboratories Limited (Parent Company)
  - Brooks Steriscience Limited (Subsidiary Company) (upto 22<sup>nd</sup> December 2022)
  - Brooks Steriscience Limited (Joint Venture)(From 22<sup>nd</sup> December 2022)
  - Steribrooks Penems Private Limited (Associate Company)

4A, Kaledonia,  
2nd Floor, Sahar Road,  
Near Andheri Station,  
Andheri (East),  
Mumbai - 400 069

Tel. +91 22 6625 6363  
Fax. +91 22 6625 6364  
E-mail. info@sgco.co.in  
www.sgco.co.in



# SGCO & Co. LLP

Chartered Accountants

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. We did not review the financial results of one subsidiary vis Brooks Steriscience Limited included in the consolidated unaudited financial results, whose financial results reflect total Income of Rs. 396.81 lakhs and Rs. 1,035.56 lakhs, total net profit/(loss) after tax of Rs.(770.83) lakhs and Rs. (1990.98) lakhs and total comprehensive income / loss of Rs (770.83) lakhs and Rs. (1990.98) lakhs, for the Quarter and Nine Months ended December 31, 2022 respectively, as considered in the consolidated unaudited financial results. These financial results have been reviewed by other auditor whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above. The consolidated financial statements also include the Group's share of net profit of Rs. 0.35 lakhs and Rs.26.86 lakhs for the Quarter and Nine Months ended December 31, 2022 respectively, as considered in the consolidated unaudited financial statements, in respect of one associate (Steribrooks Penems Private Limited) whose financial statement/ financial information/ financial results have not been limited reviewed and have been furnished to us by the Management.

Our conclusion on the Statement is not modified in respect of the above matters.

**For S G C O & Co. LLP**  
Chartered Accountants  
**Firm Registration No. 112081W/W100184**

**Suresh Murarka**

Partner

**Mem. No. 044739**

**UDIN : 23044739BGUNLN9772**



Place : Mumbai

Date : 14<sup>th</sup> February, 2023